Repealing Price Discrimination Rules for Prescription Drugs
A senate committee must act next: committee consideration.
This bill targets a long-standing antitrust law and currently lacks the broad bipartisan support needed to move through a divided Congress.
Scores run from -100 (strongly harmful) to +100 (strongly beneficial) for each group, combining impact, certainty, scope, and duration ratings of 1-5. How impact scoring works
Robinson-Patman currently limits how much extra discount big buyers can get compared to small ones for the same product. Repealing it would let large pharmacy chains, hospital systems, and retailers negotiate steeper price breaks than independent pharmacies and small stores can get, making it harder for smaller businesses to compete on price.
“The Act of June 19, 1936 (commonly known as the ``Robinson-Patman Act''; 49 Stat. 1526, chapter 592; 15 U.S.C. 13a et seq.), and the amendments made by that Act, are repealed.”
Read twice and referred to the Committee on the Judiciary.
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Introduced in Senate
The bill was officially filed and given a number. It now enters the legislative queue.
The article discusses the introduction of the Restore Prescription Drugs Discount Act by Sen. Rand Paul, which aims to reform the rebate system by repealing the Robinson-Patman Act. It argues that allowing upfront discounts could lower out-of-pocket costs and increase transparency for employers.
A report on the introduction of S. 2099, which seeks to fully repeal the Robinson-Patman Act of 1936. The bill is framed as a measure to eliminate federal restrictions on price discrimination to allow for more flexible pricing strategies in the prescription drug market.
No votes or related bills recorded for this bill yet.
Document Type
Congressional Bill
Official Title
Restore Prescription Drugs Discount Act
Analysis generated by AI. Always verify with official sources.